U.K. cost gatekeepers OK Daiichi's Lixiana; J&J Vision Care targets young females with E! partnership;

> The U.K.'s cost watchdog has recommended Daiichi Sankyo's Lixiana for treating and preventing potentially fatal blood clots. Release

> In a Phase II study, Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 prospect, Praluent, produced LDL cholesterol reductions of more than 60% in Japanese patients. Release

> Johnson & Johnson ($JNJ) Vision Care has partnered up with fashion and entertainment broadcaster E! Entertainment Television to reach a young, fashion-forward, female audience with its 1-Day Acuvue Define range of products. More

> In a Phase II study, Roche's ($RHHBY) investigational immunotherapy atezolizumab shrank tumors in people with a specific type of bladder cancer. Release

> Roche ($RHHBY) has launched its FDA-cleared diabetes app with an insulin calculator in the U.S. More

And Finally... The Obama administration has issued new rules that allow closely held for-profit corporations with religious objections to opt out of providing women with insurance coverage for contraceptives. More (sub. req.)

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?